To kick off the new year in 2024, I requested a conference call with Aptose management to seek answers to numerous questions regarding the company, their clinical program, and primarily the financing that is expected to be completed any day. I had Aptose CEO, Dr. Rice and Fletcher Payne, CFO and CBO on the call. […]
Aptose – Path Forward in 2023 With AML “Triplet Therapy”
I had a zoom meeting with Aptose’s CEO and CFO as well, to get updates regarding the new follow-up clinical trials and the timeline in 2023. The CEO was well excited with the move to the new trial in mono & combo with Venetoclax. The 1st mono therapy with 120mg (that has already started) should […]
June 15th Biotech Update
It looked like we could have gotten some momentum but it was not quite able to continue. It was not stock specific but pretty broad based. It is not as if it was a particularly bad day but that momentum that was building that I thought could get us to the $140-1 level on the […]
APTO – We Came for A Trade and Back for The Long-Term Potential
The First time I met Aptose Biosciences (APTO) was at the Bloom-Burton conference in Toronto back in May 2018 following the request of several Chimera Research Group (CRG) subscribers. They asked me to check out the company’s presentation and try to get more info about the status of the clinical hold and when we might […]
